The expansion of GLP-1 receptor agonist (GLP-1RA) therapy from a niche diabetes intervention to a defining class of cardiometabolic medicine has been one of the most consequential pharmacological developments of the past decade. The original incretin concept — that gut-derived peptides amplify post-meal insulin secretion — is now embedded in a much broader understanding of how the GLP-1 receptor regulates systemic energy balance.
The pharmacological GLP-1RAs — exenatide, liraglutide, dulaglutide, semaglutide, and the dual-agonist tirzepatide — share four core mechanisms: glucose-dependent stimulation of insulin secretion, suppression of inappropriate glucagon release, delayed gastric emptying, and central anorectic effects via arcuate-nucleus POMC neurons. The magnitude of weight loss observed with the newer molecules (15–22% of body weight in pivotal trials) substantially exceeds anything achievable with earlier-generation agents and approaches the threshold once considered achievable only with bariatric surgery.
The mechanistic frontier is now metabolic adaptation. Long-term GLP-1RA exposure produces sustained reductions in hepatic de novo lipogenesis, modest improvements in pancreatic beta-cell function indices, and emerging evidence of cardiac and renal protection independent of weight loss. The dual GIP/GLP-1 agonism of tirzepatide and the triple agonism of investigational candidates (retatrutide) suggest that further receptor engagement can yield additive metabolic effects without proportional increases in adverse-event burden.
Sources: Drucker, Cell Metabolism 2024; Holst, Physiological Reviews 2023; Müller et al., Nature Reviews Drug Discovery 2024.